EQ_OUT_1 [2025-04-01 13:23:19 -0400] 2078 Bytes | 599 tokens | Cum: 599 tkns (7.49% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Equillium (EQ) which is at 0.499 up from 0.3923. So, I pulled together a bunch of data for you to look over real fast. It's still early, 1:23:18 PM on Tue Apr 01, 2025 -0400. So, what's the verdict? You're the expert!

Here's the first list of news for Equillium:

C1 - Today 09:55AM - Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
C2 - Mar-27-25 12:49PM - Equillium pushes for breakthrough status despite missing primary endpoint
C3 - Mar-27-25 12:49PM 07:00AM - Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
C4 - Mar-27-25 12:49PM 07:00AM - Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
C5 - Feb-21-25 09:55AM - Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
C6 - Feb-10-25 12:00PM - Equillium (EQ) Upgraded to Buy: Here's What You Should Know
C7 - Feb-10-25 12:00PM 08:50AM - Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock
C8 - Feb-06-25 04:18PM - Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Equillium (EQ)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

EQ_OUT_3 [2025-04-01 13:23:25 -0400] 590 Bytes | 184 tokens | Cum: 785 tkns (9.81% of 8k)
==========================================================================

Showing C4 (chunk 1 of 1): C4:
**Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease**
Date: Mar-27-25 12:49PM 07:00AM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250327334273/en/

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250327334273/en/

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

EQ_OUT_5 [2025-04-01 13:23:26 -0400] 912 Bytes | 275 tokens | Cum: 1204 tkns (15.05% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T15:03:00Z - Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now...
A2 - 2025-03-28T13:02:07Z - Equillium stock tumbles on Phase 3 study results By Investing.com...
A3 - 2025-03-28T13:00:40Z - Equillium stock tumbles on Phase 3 study results By Investing.com...
A4 - 2025-03-28T13:02:07Z - Equillium stock tumbles on Phase 3 study results By Investing.com...
A5 - 2025-03-27T21:05:49Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Equillium (NASDAQ:EQ), Edap TMS (N...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

EQ_OUT_7 [2025-04-01 13:23:27 -0400] 1098 Bytes | 284 tokens | Cum: 1490 tkns (18.62% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now**Date: 2025-04-01Source: {'uri': 'nasdaq.com', 'dataType': 'news', 'title': 'NASDAQ Stock Market'}URL: https://www.nasdaq.com/articles/equillium-eq-may-find-bottom-soon-heres-why-you-should-buy-stock-nowShares of Equillium, Inc. (EQ) have been struggling lately and have lost 52.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.

While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this company is a solid fundamental factor that enhances the prospects of a trend reversa

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

EQ_OUT_9 [2025-04-01 13:23:28 -0400] 1004 Bytes | 328 tokens | Cum: 1820 tkns (22.75% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-09-22T04:30:00Z - Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight
B2 - 2024-09-16T13:00:00Z - Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy
B3 - 2024-05-09T21:35:07Z - Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
B4 - 2024-05-08T22:25:06Z - Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
B5 - 2024-04-01T13:52:00Z - 5 Stocks That More Than Doubled in Q1 With More Gains Ahead
B6 - 2024-03-26T17:45:27Z - Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

EQ_OUT_11 [2025-04-01 13:23:33 -0400] 839 Bytes | 246 tokens | Cum: 2068 tkns (25.85% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/09/16/2946672/0/en/Vivtex-Enters-New-Research-Agreement-with-Equillium-to-Develop-GI-targeted-Formulations-for-its-First-in-Class-Oral-Bi-Specific-Peptide-Therapy.htmlVivtex and Equillium have entered a research collaboration to develop an optimized oral version of Equillium's EQ302, a bi-specific peptide inhibitor of IL-15 and IL-21, for the treatment of gastrointestinal disorders.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

EQ_OUT_13 [2025-04-01 13:23:34 -0400] 799 Bytes | 202 tokens | Cum: 2374 tkns (29.68% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled Selected Fin Data and our consolida...

S2 - 2025-03-27 8-K Item 2.02 Results of Oper and Fin Cond.

On March 27, 2025, Equillium, Inc. (the Company) announced its financial results for the fourth quarter and full year ended December 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

EQ_OUT_15 [2025-04-01 13:23:39 -0400] 1098 Bytes | 224 tokens | Cum: 2600 tkns (32.50% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled Selected Financial Data and our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion and analysis contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in the section entitled Risk Factors and in other parts of this Annual Report on Form 10-K. Please also see the section entitled Special Note Regarding Forward-Looking Statements.

Overview

We are a clinical-stage biotechno

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

EQ_OUT_17 [2025-04-01 13:23:51 -0400] 9897 Bytes | 2989 tokens | Cum: 5706 tkns (71.33% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-----------------------+
| Volume: 106,284 | Perf Month: -30.69% | Option/Short: Yes / Yes | Sales Y/Y TTM: 13.89% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 831.04K | Perf Quarter: -28.10% | Short Float: 2.08% | ROE: -38.75% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 0.22 | Index: - | Short Ratio: 0.44 | ROI: -41.91% |
+---------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 34.87 | Market Cap: 17.77M | Short Interest: 0.36M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.09 | Shs Outstand: 35.56M | Beta: 1.86 | EPS Surprise: 48.39% |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA20: -29.59% | Shs Float: 17.44M | Sales Q/Q: -52.32% | P/E: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -33.05% | Inst Own: 5.28% | Sales past 5Y: 28.57% | Earnings: Mar 27 BMO |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -37.30% | Insider Own: 50.77% | Employees: 35 | |
+---------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: -37.31% | Insider Trans: -0.21% | Debt/Eq: 0.02 | |
+---------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Equillium, Inc. (EQ) by Troupin Barbara (Unknown Title) on 2025-02-14
- Director Stock Option (right to buy): 40000 shares at $N/A (D)
- Director Stock Option (right to buy): 40000 shares at $N/A (D)

Inside Trans: Equillium, Inc. (EQ) by Tom Penny (Principal Accounting Officer) on 2025-02-14
- Employee Stock Option (right to buy): 65000 shares at $N/A (D)
- Employee Stock Option (right to buy): 65000 shares at $N/A (D)
- Employee Stock Option (right to buy): 45000 shares at $N/A (D)
- Employee Stock Option (right to buy): 45000 shares at $N/A (D)
- Employee Stock Option (right to buy): 40000 shares at $N/A (D)
- Employee Stock Option (right to buy): 40000 shares at $N/A (D)
- Employee Stock Option (right to buy): 60000 shares at $N/A (D)
- Employee Stock Option (right to buy): 60000 shares at $N/A (D)
- Employee Stock Option (right to buy): 40000 shares at $N/A (D)
- Employee Stock Option (right to buy): 40000 shares at $N/A (D)
- Employee Stock Option (right to buy): 100000 shares at $N/A (D)
- Employee Stock Option (right to buy): 100000 shares at $N/A (D)

Inside Trans: Equillium, Inc. (EQ) by Keyes Jason A (Chief Financial Officer) on 2025-02-14
- Employee Stock Option (right to buy): 70000 shares at $N/A (D)
- Employee Stock Option (right to buy): 70000 shares at $N/A (D)
- Employee Stock Option (right to buy): 90000 shares at $N/A (D)
- Employee Stock Option (right to buy): 90000 shares at $N/A (D)
- Employee Stock Option (right to buy): 100000 shares at $N/A (D)
- Employee Stock Option (right to buy): 100000 shares at $N/A (D)
- Employee Stock Option (right to buy): 125000 shares at $N/A (D)
- Employee Stock Option (right to buy): 125000 shares at $N/A (D)
- Employee Stock Option (right to buy): 175000 shares at $N/A (D)
- Employee Stock Option (right to buy): 175000 shares at $N/A (D)

Inside Trans: Equillium, Inc. (EQ) by MANIAN BALA S (Unknown Title) on 2025-02-14
- Director Stock Option (right to buy): 12000 shares at $N/A (D)
- Director Stock Option (right to buy): 12000 shares at $N/A (D)
- Director Stock Option (right to buy): 24000 shares at $N/A (D)
- Director Stock Option (right to buy): 24000 shares at $N/A (D)
- Director Stock Option (right to buy): 20634 shares at $N/A (D)
- Director Stock Option (right to buy): 20634 shares at $N/A (D)
- Director Stock Option (right to buy): 20770 shares at $N/A (D)
- Director Stock Option (right to buy): 20770 shares at $N/A (D)
- Director Stock Option (right to buy): 20000 shares at $N/A (D)
- Director Stock Option (right to buy): 20000 shares at $N/A (D)

Inside Trans: Equillium, Inc. (EQ) by DEMSKI MARTHA J (Unknown Title) on 2025-02-14
- Director Stock Option (right to buy): 12000 shares at $N/A (D)
- Director Stock Option (right to buy): 12000 shares at $N/A (D)
- Director Stock Option (right to buy): 24000 shares at $N/A (D)
- Director Stock Option (right to buy): 24000 shares at $N/A (D)
- Director Stock Option (right to buy): 20770 shares at $N/A (D)
- Director Stock Option (right to buy): 20770 shares at $N/A (D)
- Director Stock Option (right to buy): 20000 shares at $N/A (D)
- Director Stock Option (right to buy): 20000 shares at $N/A (D)

Inside Trans: Equillium, Inc. (EQ) by Pruzanski Mark (Unknown Title) on 2025-02-14
- Director Stock Option (right to buy): 12000 shares at $N/A (D)
- Director Stock Option (right to buy): 12000 shares at $N/A (D)
- Director Stock Option (right to buy): 24000 shares at $N/A (D)
- Director Stock Option (right to buy): 24000 shares at $N/A (D)
- Director Stock Option (right to buy): 20770 shares at $N/A (D)
- Director Stock Option (right to buy): 20770 shares at $N/A (D)
- Director Stock Option (right to buy): 20000 shares at $N/A (D)
- Director Stock Option (right to buy): 20000 shares at $N/A (D)

Inside Trans: Equillium, Inc. (EQ) by Steel Bruce D. (President and CEO) on 2025-02-14
- Employee Stock Option (right to buy): 44352 shares at $N/A (D)
- Employee Stock Option (right to buy): 44352 shares at $N/A (D)
- Employee Stock Option (right to buy): 100000 shares at $N/A (D)
- Employee Stock Option (right to buy): 100000 shares at $N/A (D)
- Employee Stock Option (right to buy): 60000 shares at $N/A (D)
- Employee Stock Option (right to buy): 60000 shares at $N/A (D)
- Employee Stock Option (right to buy): 100110 shares at $N/A (D)
- Employee Stock Option (right to buy): 100110 shares at $N/A (D)
- Employee Stock Option (right to buy): 245000 shares at $N/A (D)
- Employee Stock Option (right to buy): 245000 shares at $N/A (D)
- Employee Stock Option (right to buy): 325000 shares at $N/A (D)
- Employee Stock Option (right to buy): 325000 shares at $N/A (D)
- Employee Stock Option (right to buy): 410000 shares at $N/A (D)
- Employee Stock Option (right to buy): 410000 shares at $N/A (D)

Inside Trans: Equillium, Inc. (EQ) by BRADBURY DANIEL (EXECUTIVE CHAIRMAN) on 2025-02-14
- Employee Stock Option (right to buy): 90000 shares at $N/A (D)
- Employee Stock Option (right to buy): 90000 shares at $N/A (D)
- Employee Stock Option (right to buy): 36000 shares at $N/A (D)
- Employee Stock Option (right to buy): 36000 shares at $N/A (D)
- Employee Stock Option (right to buy): 28708 shares at $N/A (D)
- Employee Stock Option (right to buy): 28708 shares at $N/A (D)
- Employee Stock Option (right to buy): 36000 shares at $N/A (D)
- Employee Stock Option (right to buy): 36000 shares at $N/A (D)
- Employee Stock Option (right to buy): 38000 shares at $N/A (D)
- Employee Stock Option (right to buy): 38000 shares at $N/A (D)
- Employee Stock Option (right to buy): 50000 shares at $N/A (D)
- Employee Stock Option (right to buy): 50000 shares at $N/A (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 41095000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -8067000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.5
Average Volume: 138717.36
30-Day High: 0.8199
30-Day Low: 0.3923

[Detailed Financials: TTM 2024]
- Total Assets: $25,604,000.0
- Total Liabilities: $6,543,000.0
- Total Equity: $19,061,000.0
- Current Assets: $24,978,000.0
- Current Liabilities: $6,356,000.0

[Income Statement: TTM 2024]
- Revenue: $41,095,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.23

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-5,048,000.0

[Detailed Financials: FY 2024]
- Total Assets: $25,604,000.0
- Total Liabilities: $6,543,000.0
- Total Equity: $19,061,000.0
- Current Assets: $24,978,000.0
- Current Liabilities: $6,356,000.0

[Income Statement: FY 2024]
- Revenue: $41,095,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.23

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-5,048,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

EQ_OUT_19 [2025-04-01 13:23:53 -0400] 676 Bytes | 167 tokens | Cum: 6160 tkns (77.00% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

EQ_IN_21 [2025-04-01 13:23:54 -0400] 126 Bytes | 29 tokens | Cum: 6217 tkns (77.71% of 8k)
==========================================================================

====================================
[2025-04-01 13:23:54] # Analysis Completed
Elapsed Time: 35.64 seconds